Compare KMT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | NUVB |
|---|---|---|
| Founded | 1938 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1994 | 2020 |
| Metric | KMT | NUVB |
|---|---|---|
| Price | $29.66 | $5.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $36.00 | $11.38 |
| AVG Volume (30 Days) | 1.3M | ★ 4.4M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 268.33 | 71.56 |
| EPS | ★ 4.42 | N/A |
| Revenue | ★ $2,356,698,000.00 | $62,902,000.00 |
| Revenue This Year | $14.24 | $203.82 |
| Revenue Next Year | $7.57 | $58.18 |
| P/E Ratio | $6.75 | ★ N/A |
| Revenue Growth | 19.82 | ★ 698.96 |
| 52 Week Low | $20.35 | $3.00 |
| 52 Week High | $43.81 | $9.75 |
| Indicator | KMT | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 39.53 |
| Support Level | $28.40 | $5.28 |
| Resistance Level | $31.15 | $6.25 |
| Average True Range (ATR) | 0.84 | 0.28 |
| MACD | 0.16 | -0.11 |
| Stochastic Oscillator | 40.66 | 15.67 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.